Betaseron® [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2016.
Copaxone® [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2018.
Avonex® [package insert]. Cambridge, MA: Biogen, Inc.; 2016.
Bakhuraysah MM, Siatskas C, Petratos S. Hematopoietic stem cell transplantation for multiple sclerosis: is it a clinical reality? Stem Cell Res Ther. 2016;7:12.
Rebif® [package insert]. Rockland, MA: EMD Serono; 2015.
Tysabri® [package insert]. Cambridge, MA: Biogen Inc.; 2018.
Novantrone® [package insert]. EMD Serono, Inc.: Rockland, MD; 2008.
Extavia® [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2016.
Gilenya® [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.
Aubagio® [package insert]. Cambridge, MA: Genzyme Corporation; 2016.
Tecfidera® [package insert]. Cambridge, MA: Biogen Inc.; 2017.
Lemtrada® [package insert]. Cambridge, MA: Genzyme Corporation; 2019.
Plegridy® [package insert]. Cambridge, MA: Biogen Inc.; 2016.
Giovannoni G, Comi G, Cook S, et al; CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416-426.
Ocrevus® [package insert]. South San Francisco, CA: Genentech, Inc.; 2017.
Giovannoni G. Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm. Curr Opin Neurol. 2018;31:233-243.
Nath A, Berger JR. Complications of immunosuppressive/immunomodulatory therapy in neurological diseases. Curr Treat Options Neurol. 2012;14:241-255.
Holmøy T, von der Lippe H, Leegaard TM. Listeria monocytogenes infection associated with alemtuzumab -- a case for better preventive strategies. BMC Neurol. 2017;17:65.
Arvin AM, Wolinsky JS, Kappos L, et al. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol. 2015;72:31-39.
Williamson EM, Chahin S, Berger JR. Vaccines in multiple sclerosis. Curr Neurol Neurosci Rep. 2016;16:36.
Centers for Disease Control and Prevention. Recommended Adult Immunization Schedule for ages 19 years or older, United States, 2019. https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html Accessed March 7, 2019.
Major EO, Yousry TA, Clifford DB. Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. Lancet Neurol. 2018;17:467-480.
Triplett J, Kermode AG, Corbett A, et al. Warts and all: Fingolimod and unusual HPV-associated lesions. Mult Scler. 2018 Nov 14:1352458518807088. doi: 10.1177/1352458518807088. [Epub ahead of print]
Durrieu G, Dardonville Q, Clanet M, et al. Cervical dysplasia in a patient with multiple sclerosis treated with natalizumab. Fundam Clin Pharmacol. 2019;33:125-126.
US Preventive Services Task Force, Curry SJ, Krist AH, et al. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;320:674-686.
Epstein DJ, Dunn J, Deresinski S. Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management. Open Forum Infect Dis. 2018;5:ofy174.
Barmettler S, Ong MS, Farmer JR, et al. Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open. 2018;1:e184169.
Stokmaier D, Winthrop K, Chognot C, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis. Neurology. 2018;90(15 suppl):S36.002.
Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:e44-100.
Zhovtis Ryerson L, Foley J, Chang I, et al. Natalizumab extended interval dosing is associated with a reduction in progressive multifocal leukoencephalopathy risk in the TOUCH^® registry. Presented at: ACTRIMS Forum 2018; February 1-3, 2018; San Diego, California. Poster LB250.
Landi D, De Rossi N, Zagaglia S, et al; Italian PML study group. No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology. 2017;88:1144-1152.
Forrestel AK, Modi BG, Longworth S, et al. Primary cutaneous cryptococcus in a patient with multiple sclerosis treated with fingolimod. JAMA Neurol. 2016;73:355-356.
Enriquez-Marulanda A, Valderrama-Chaparro J, Parrado L, et al. Cerebral toxoplasmosis in an MS patient receiving fingolimod. Mult Scler Relat Disord. 2017;18:106-108.
Artemiadis AK, Nikolaou G, Kolokythopoulos D, et al. Visceral leishmaniasis infection in a fingolimod-treated multiple sclerosis patient. Mult Scler. 2015;21:795-796.
Tully T, Barkley A, Silber E. Kaposi sarcoma in a patient with relapsing-remitting multiple sclerosis receiving fingolimod. Neurology. 2015;84:1999-2001.
Mahajan KR, Ko JS, Tetzlaff MT, et al. Merkel cell carcinoma with fingolimod treatment for multiple sclerosis: a case report. Mult Scler Relat Disord. 2017;17:12-14.
Lehmann-Horn K, Penkert H, Grein P, et al. PML during dimethyl fumarate treatment of multiple sclerosis: how does lymphopenia matter? Neurology. 2016;87:440-441.
Ruggieri S, Logoteta A, Martini G, et al. Listeria monocytogenes-induced rhombencephalitis in a patient with multiple sclerosis treated with dimethyl fumarate. JAMA Neurol. 2018;75:762-763.
Cook S, Vermersch P, Comi G, et al; CLARITY Study Group. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult Scler. 2011;17:578-593.
Baker D, Herrod SS, Alvarez-Gonzalez C, et al. Both cladribine and alemtuzumab may affect MS via B-cell depletion. Neurol Neuroimmunol Neuroinflamm. 2017;4:e360.
Hauser SL, Kappos L, Montalban X, et al. Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Presented at: 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 10-12, 2018; Berlin, Germany. Poster P1229.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator

Gavin Giovannoni, MBBCh, PhD

Professor and Chair of Neurology
Barts and The London School of Medicine and Dentistry
London, United Kingdom

Disclosures

Disclosure: Gavin Giovannoni , MBBCh, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Bayer AG; Biogen Idec Inc.; Canbex Therapeutics Ltd.; Eisai Inc.; Elan Pharmaceuticals, LLC.; FivePrime Therapeutics; Genentech, Inc.; Genzyme Corporation; GlaxoSmithKline; GW Pharmaceuticals plc.; Ironwood Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche; Sanofi; Synthon BV; Teva Pharmaceuticals USA; UCB Pharma, Inc.; Vertex Pharmaceuticals Incorporated

Panelist

Joseph R. Berger, MD

Professor of Neurology
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Disclosures

Disclosure: Joseph R. Berger, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alcimed; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Bayer AG; Biogen; Bristol-Myers Squibb Company; EMD Serono, Inc.; Excision BioTherapeutics; Genzyme Corporation; Inhibikase Therapeutics, Inc.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Merck & Co., Inc.; Millennium Pharmaceuticals, Inc; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sanofi; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Biogen

Editors

Catherine Friederich Murray

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Catherine Friederich Murray has disclosed no relevant financial relationships.

Shira Berman

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Shira Berman has disclosed no relevant financial relationships.

CME Reviewer

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC

Mitigating Infection Risk With DMT in MS: Now and in the Future

Authors: Gavin Giovannoni, MBBCh, PhD; Joseph R. Berger, MD
CME / ABIM MOC Released: 3/27/2019
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 3/27/2020

Start Activity

Target Audience and Goal Statement

This activity is intended for neurologists, primary care physicians, and obstetricians and gynecologists.

The goal of this activity is to assist healthcare professionals in assessing infection risk associated with the use of established and investigational disease modifying therapies (DMTs) in patients with multiple sclerosis (MS) and outlining strategies for infection risk reduction.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Common infections associated with different classes of DMTs used for the treatment of MS
- Approaches for reducing infection risk in patients receiving a DMT for the treatment of MS

Disclosures

Moderator

Gavin Giovannoni, MBBCh, PhD

Professor and Chair of Neurology
Barts and The London School of Medicine and Dentistry
London, United Kingdom

Disclosures

Disclosure: Gavin Giovannoni , MBBCh, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Bayer AG; Biogen Idec Inc.; Canbex Therapeutics Ltd.; Eisai Inc.; Elan Pharmaceuticals, LLC.; FivePrime Therapeutics; Genentech, Inc.; Genzyme Corporation; GlaxoSmithKline; GW Pharmaceuticals plc.; Ironwood Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche; Sanofi; Synthon BV; Teva Pharmaceuticals USA; UCB Pharma, Inc.; Vertex Pharmaceuticals Incorporated

Panelist

Joseph R. Berger, MD

Professor of Neurology
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Disclosures

Disclosure: Joseph R. Berger, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alcimed; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Bayer AG; Biogen; Bristol-Myers Squibb Company; EMD Serono, Inc.; Excision BioTherapeutics; Genzyme Corporation; Inhibikase Therapeutics, Inc.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Merck & Co., Inc.; Millennium Pharmaceuticals, Inc; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sanofi; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Biogen

Editors

Catherine Friederich Murray

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Catherine Friederich Murray has disclosed no relevant financial relationships.

Shira Berman

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Shira Berman has disclosed no relevant financial relationships.

CME Reviewer

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit--AMPERSAND--amp;trade;, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Neurology & Neurosurgery

CME / ABIM MOC

Mitigating Infection Risk With DMT in MS: Now and in the Future

Authors: Gavin Giovannoni, MBBCh, PhD; Joseph R. Berger, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 3/27/2019

Valid for credit through: 3/27/2020

processing....

A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

Download Now

CME / ABIM MOC Information

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Moderator

Gavin Giovannoni, MBBCh, PhD

Panelist

Joseph R. Berger, MD

Editors

Catherine Friederich Murray

Shira Berman

CME Reviewer

Nafeez Zawahir, MD

Peer Reviewer

CME / ABIM MOC

Mitigating Infection Risk With DMT in MS: Now and in the Future

Target Audience and Goal Statement

Disclosures

Moderator

Gavin Giovannoni, MBBCh, PhD

Panelist

Joseph R. Berger, MD

Editors

Catherine Friederich Murray

Shira Berman

CME Reviewer

Nafeez Zawahir, MD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Mitigating Infection Risk With DMT in MS: Now and in the Future